K2B Therapeutics

K2B Therapeutics is a private preclinical oncology biotech developing targeted conjugate therapeutics designed to exploit the CD47-SIRPalpha axis in cancer. The company is advancing engineered SIRPalpha-based protein-drug conjugates and protein-siRNA conjugates intended to selectively deliver payloads to CD47-upregulated tumor cells while avoiding some of the size and Fc-related liabilities associated with antibodies. K2B positions its approach as tumor-agnostic, with a modular platform intended to support multiple payload types and collaboration opportunities with biopharma partners. The company appears to be building an early discovery pipeline with a stated line of sight to the clinic, but it has not publicly disclosed detailed named clinical assets. Its technology has roots in intellectual property co-assigned with the Korea Institute of Science and Technology.